aidsВИЧ-инфекция и иммуносупрессииHIV Infection and Immunosuppressive Disorders2077-9828Baltic Medical Education Center10.22328/2077-9828-2020-12-1-22-31aids-520Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОРANALYTICAL REVIEWСТРАТЕГИИ ИЗЛЕЧЕНИЯ ВИЧ-ИНФЕКЦИИ: ОСНОВНЫЕ МЕТОДОЛОГИЧЕСКИЕ ПОДХОДЫ И ПРОБЛЕМЫ ИХ РЕАЛИЗАЦИИHIV INFECTION CURE STRATEGIES: BASIC METHODOLOGICAL APPROACHES AND DIFFICULTIES OF THEIR IMPLEMENTATIONБобковаМ. Р.BobkovaM. R.

доктор биологических наук, заведующая лабораторией вирусов лейкозов

123098, Москва, ул. Гамалеи, д. 16

mrbobkova@mail.ruИнститут вирусологии им. Д. И. Ивановского ФГБУ «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи» Минздрава РоссииРоссияIvanovsky Institute of Virology, N. F. Gamaleya Federal Research Center for Epidemiology and MicrobiologyRussian Federation2020250520201212231Copyright © Бобкова М.Р., 20202020Бобкова М.Р.Bobkova M.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hiv.bmoc-spb.ru/jour/article/view/520

Обзорная статья посвящена актуальной теме эрадикации и функционального излечения ВИЧ-инфекции. В статье очень кратко рассматриваются вопросы, касающиеся истории открытия, характеристик и происхождения основных резервуаров ВИЧ, возможные подходы к их ликвидации, примеры клинического излечения ВИЧ-инфекции и принципиальные направления разработки средств, способных производить направленное уничтожение клеточных резервуаров ВИЧ. Очерчен круг методологических подходов к измерению объема резервуаров, охарактеризованы их достоинства и недостатки. Описан порядок проведения клинических испытаний средств эрадикации ВИЧ, включающих период аналитического прерывания антиретровирусной терапии.

The review article is devoted to the state-of-the-art of eradication and functional cure of HIV infection. The issues related to the history of the discovery, characteristics and origin of the main HIV reservoirs, possible approaches to their elimination, exam- ples of the clinical cure of HIV infection and the principal directions of developing tools for targeted destruction of latently infect- ed HIV cell reservoirs are discussed shortly. The circle of methodological approaches for measuring the reservoirs volume is outlined; their advantages and disadvantages are characterized. The procedure for HIV eradication agents’ clinical trials, including the period of analytical interruption of antiretroviral therapy, is described.

ВИЧантиретровирусная терапиярезервуарэрадикацияфункциональное излечениеHIVantiretroviral therapyreservoireradicationfunctional cureИсследование выполнено с привлечением средств гранта Российского научного фонда (проект №15-15-00050-П)ReferencesBarton K., Winckelmann A., Palmer S. HIV-1 Reservoirs During Suppressive Therapy // Trends Microbiol. 2016. Vol. 24. No. 5. Р. 345–355.Barton K., Winckelmann A., Palmer S. HIV-1 Reservoirs During Suppressive Therapy // Trends Microbiol. 2016. Vol. 24. No. 5. Р. 345–355.Doyle, T. Geretti, A. M. Low-level viraemia on HAART: significance and management // Curr. Opin. Infect. Dis. 2012. Vol. 25. No. 1. Р. 17–25.Doyle, T. Geretti, A. M. Low-level viraemia on HAART: significance and management // Curr. Opin. Infect. Dis. 2012. Vol. 25. No. 1. Р. 17–25.Sarmati L., D’Ettorre G., Parisi S.G. et al. HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective // Curr. HIV Res. 2015. Vol. 13. No. 3. Р. 250–257.Sarmati L., D’Ettorre G., Parisi S.G. et al. HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective // Curr. HIV Res. 2015. Vol. 13. No. 3. Р. 250–257.Spivak A.M., Planelles V. HIV-1 Eradication: Early Trials (and Tribulations) // Trends Mol. Med. 2016. Vol. 22. No. 1. Р. 10–27.Spivak A.M., Planelles V. HIV-1 Eradication: Early Trials (and Tribulations) // Trends Mol. Med. 2016. Vol. 22. No. 1. Р. 10–27.Trono D., Van Lint C., Rouzioux C. et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals //Science. 2010. Vol. 329. No. 5988. Р. 174–180.Trono D., Van Lint C., Rouzioux C. et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals //Science. 2010. Vol. 329. No. 5988. Р. 174–180.Sahu G.K. Potential implication of residual viremia in patients on effective antiretroviral therapy // AIDS Res Hum Retroviruses. 2015. Vol. 31. No. 1. Р. 25–35.Sahu G.K. Potential implication of residual viremia in patients on effective antiretroviral therapy // AIDS Res Hum Retroviruses. 2015. Vol. 31. No. 1. Р. 25–35.Pham H.T., Mesplede T. The latest evidence for possible HIV-1 curative strategies // Drugs Context. 2018. Vol. 7. Р. 212522.Pham H.T., Mesplede T. The latest evidence for possible HIV-1 curative strategies // Drugs Context. 2018. Vol. 7. Р. 212522.Costiniuk C.T., Jenabian M.A. HIV reservoir dynamics in the face of highly active antiretroviral therapy // AIDS Patient Care STDS. 2015. Vol. 29, Nо. 2. Р. 55–68.Costiniuk C.T., Jenabian M.A. HIV reservoir dynamics in the face of highly active antiretroviral therapy // AIDS Patient Care STDS. 2015. Vol. 29, Nо. 2. Р. 55–68.Rose R., Nolan D.J., Maidji E. et al. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure // AIDS Res Hum Retroviruses. 2018. Vol. 34, Nо. 1. Р. 3–8.Rose R., Nolan D.J., Maidji E. et al. Eradication of HIV from Tissue Reservoirs: Challenges for the Cure // AIDS Res Hum Retroviruses. 2018. Vol. 34, Nо. 1. Р. 3–8.Castro-Gonzalez S., Colomer-Lluch M., Serra-Moreno R. Barriers for HIV Cure: The Latent Reservoir // AIDS Res Hum Retroviruses. 2018. Vol. 34. No. 9. Р. 739–759.Castro-Gonzalez S., Colomer-Lluch M., Serra-Moreno R. Barriers for HIV Cure: The Latent Reservoir // AIDS Res Hum Retroviruses. 2018. Vol. 34. No. 9. Р. 739–759.Romani B., Allahbakhshi E. Underlying mechanisms of HIV-1 latency // Virus Genes. 2017. Vol. 53. No. 3. Р. 329–339.Romani B., Allahbakhshi E. Underlying mechanisms of HIV-1 latency // Virus Genes. 2017. Vol. 53. No. 3. Р. 329–339.Van Marle G., Church D. L., van der Meer F. et al. Combating the HIV reservoirs // Biotechnol Genet Eng. Rev. 2018. Vol. 34. No. 1. Р. 76–89.Van Marle G., Church D. L., van der Meer F. et al. Combating the HIV reservoirs // Biotechnol Genet Eng. Rev. 2018. Vol. 34. No. 1. Р. 76–89.Deeks S.G., Lewin S.R., Ross A.L. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 // Nat. Med. 2016. Vol. 22. No. 8. Р. 839–850.Deeks S.G., Lewin S.R., Ross A.L. et al. International AIDS Society global scientific strategy: towards an HIV cure 2016 // Nat. Med. 2016. Vol. 22. No. 8. Р. 839–850.Kimata J.T., Rice A.P., Wang J. Challenges and strategies for the eradication of the HIV reservoir // Curr. Opin. Immunol. 2016. Vol. 42. Р. 65–70.Kimata J.T., Rice A.P., Wang J. Challenges and strategies for the eradication of the HIV reservoir // Curr. Opin. Immunol. 2016. Vol. 42. Р. 65–70.Allers K., Hutter G., Hofmann J. et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation // Blood. 2011. Vol. 117. Nо. 10. Р. 2791–2799.Allers K., Hutter G., Hofmann J. et al. Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation // Blood. 2011. Vol. 117. Nо. 10. Р. 2791–2799.Yukl S.A., Boritz E., Busch M. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient // PLoS Pathog. 2013. Vol. 9. Nо. 5. pp. e1003347.Yukl S.A., Boritz E., Busch M. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient // PLoS Pathog. 2013. Vol. 9. Nо. 5. pp. e1003347.Gupta R.K., Abdul-Jawad S., McCoy L.E. et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation // Nature. 2019. Vol. 568. Nо. 7751. Р. 244–248.Gupta R.K., Abdul-Jawad S., McCoy L.E. et al. HIV-1 remission following CCR5Delta32/Delta32 haematopoietic stem-cell transplantation // Nature. 2019. Vol. 568. Nо. 7751. Р. 244–248.Wang H., Yang H. Gene-edited babies: What went wrong and what could go wrong // PLoS Biol. 2019. Vol. 17. Nо. 4. Р. e3000224.Wang H., Yang H. Gene-edited babies: What went wrong and what could go wrong // PLoS Biol. 2019. Vol. 17. Nо. 4. Р. e3000224.Li J.R., Walker S., Nie J.B. et al. Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance // J. Zhejiang Univ Sci. B. 2019. Vol. 20. Nо. 1. Р. 32–38.Li J.R., Walker S., Nie J.B. et al. Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance // J. Zhejiang Univ Sci. B. 2019. Vol. 20. Nо. 1. Р. 32–38.Jean M.J., Fiches G., Hayashi T. et al. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors // AIDS Res Hum Retroviruses. 2019. Vol. 35. Nо. 1. Р. 1–24.Jean M.J., Fiches G., Hayashi T. et al. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors // AIDS Res Hum Retroviruses. 2019. Vol. 35. Nо. 1. Р. 1–24.Saez-Cirion A., Bacchus C., Hocqueloux L. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study // PLoS Pathog. 2013. Vol. 9. Nо. 3. Р. e1003211.Saez-Cirion A., Bacchus C., Hocqueloux L. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study // PLoS Pathog. 2013. Vol. 9. Nо. 3. Р. e1003211.Darcis G., Van Driessche B., Van Lint C. HIV Latency: Should We Shock or Lock? // Trends Immunol. 2017. Vol.38. Nо. 3. Р. 217–228.Darcis G., Van Driessche B., Van Lint C. HIV Latency: Should We Shock or Lock? // Trends Immunol. 2017. Vol.38. Nо. 3. Р. 217–228.Perreau M., Banga R., Pantaleo G. Targeted Immune Interventions for an HIV-1 Cure // Trends Mol. Med. 2017. Vol. 23. Nо. 10. Р. 945–961.Perreau M., Banga R., Pantaleo G. Targeted Immune Interventions for an HIV-1 Cure // Trends Mol. Med. 2017. Vol. 23. Nо. 10. Р. 945–961.Delagreverie H.M., Delaugerre C., Lewin S.R. et al. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents // Open Forum Infect. Dis. 2016. Vol. 3. Nо. 4. Р. ofw189.Delagreverie H.M., Delaugerre C., Lewin S.R. et al. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents // Open Forum Infect. Dis. 2016. Vol. 3. Nо. 4. Р. ofw189.Margolis D.M., Garcia J.V., Hazuda D.J. et al. Latency reversal and viral clearance to cure HIV-1 // Science. 2016. Vol. 353. Nо. 6297. Р. aaf6517.Margolis D.M., Garcia J.V., Hazuda D.J. et al. Latency reversal and viral clearance to cure HIV-1 // Science. 2016. Vol. 353. Nо. 6297. Р. aaf6517.Barton K.M., Palmer S.E. How to Define the Latent Reservoir: Tools of the Trade // Curr. HIV/AIDS Rep. 2016. Vol. 13. Nо. 2. Р. 77–84.Barton K.M., Palmer S.E. How to Define the Latent Reservoir: Tools of the Trade // Curr. HIV/AIDS Rep. 2016. Vol. 13. Nо. 2. Р. 77–84.Siliciano J.D., Siliciano R.F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication- competent virus in HIV-1-infected individuals // Methods Mol. Biol. 2005. Vol. 304. Р. 3–15.Siliciano J.D., Siliciano R.F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication- competent virus in HIV-1-infected individuals // Methods Mol. Biol. 2005. Vol. 304. Р. 3–15.Kiselinova M., Pasternak A.O., De Spiegelaere W. et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA // PLoS One. 2014. Vol. 9. Nо. 1. Р. e85999.Kiselinova M., Pasternak A.O., De Spiegelaere W. et al. Comparison of droplet digital PCR and seminested real-time PCR for quantification of cell-associated HIV-1 RNA // PLoS One. 2014. Vol. 9. Nо. 1. Р. e85999.Rouzioux C., Avettand-Fenoel V. Total HIV DNA: a global marker of HIV persistence // Retrovirology. 2018. Vol. 15. Nо. 1. Р. 30.Rouzioux C., Avettand-Fenoel V. Total HIV DNA: a global marker of HIV persistence // Retrovirology. 2018. Vol. 15. Nо. 1. Р. 30.Sharaf R.R., Li J.Z. The Alphabet Soup of HIV Reservoir Markers // Curr. HIV/AIDS Rep. 2017. Vol. 14. Nо. 2. Р. 72–81.Sharaf R.R., Li J.Z. The Alphabet Soup of HIV Reservoir Markers // Curr. HIV/AIDS Rep. 2017. Vol. 14. Nо. 2. Р. 72–81.Hodel F., Patxot M., Snaka T. et al. HIV-1 latent reservoir: size matters // Future Virol. 2016. Vol. 11. Nо. 12. Р. 785–794.Hodel F., Patxot M., Snaka T. et al. HIV-1 latent reservoir: size matters // Future Virol. 2016. Vol. 11. Nо. 12. Р. 785–794.Cromer D., Pinkevych M., Rasmussen T.A. et al. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? // J. Virol. 2017. Vol. 91. No. 24.Cromer D., Pinkevych M., Rasmussen T.A. et al. Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? // J. Virol. 2017. Vol. 91. No. 24.Li J.Z., Etemad B., Ahmed H. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption // AIDS. 2016. Vol. 30. No. 3. Р. 343–353.Li J.Z., Etemad B., Ahmed H. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption // AIDS. 2016. Vol. 30. No. 3. Р. 343–353.Salantes D.B., Zheng Y., Mampe F. et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption // J. Clin. Invest. 2018. Vol. 128. Nо 7. Р. 3102–3115.Salantes D.B., Zheng Y., Mampe F. et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption // J. Clin. Invest. 2018. Vol. 128. Nо 7. Р. 3102–3115.

The authors declare that there are no conflicts of interest present.